Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and Other Infectious Diseases
Q BioMed Inc., a commercial stage biotech company, announced today that its research partner Mannin Research Inc. (Mannin) is developing new therapeutics to treat a variety of vascular diseases, including the new coronavirus which originated in Wuhan, China, with a rapidly rising number of deaths and confirmed cases. Coronavirus has been declared a Global Health Emergency by the World Health Organization (WHO).
Mannin is developing a unique set of therapeutics that target a variety of vascular diseases. Its lead research platform targets the activation of the Angiopoietin-Tie2 signaling pathway. While Mannin is not generating a vaccine against infectious diseases, it is developing a new class of therapeutics that may increase the survival rate of patients by reducing endothelial dysfunction and severity of infectious and other diseases through enhancement of host-directed therapeutic response.
"We are working closely with our technology research partner Mannin to develop a potential adjunct treatment for various infectious diseases like the coronavirus. These types of outbreaks are not uncommon. H1N1, SARS, Ebola, pneumonia, influenza and others all can cause vascular leakage and respiratory distress in patients, which can be fatal in the most severe cases," stated Q BioMed CEO Denis Corin.
Dr. George N. Nikopoulos, President and CEO of Mannin, "Mannin's research team and collaborations in Canada, Germany, and the United States, are working to develop novel drugs to treat vascular leakage and endothelial dysfunction, which is common in severe cases of influenza, as well as in the current coronavirus outbreak. Seeing the potential to make positive impact upon patients' lives, drives our team to strive further each day."
In September 2019, the German state of Saxony awarded Mannin approximately a US $7.7 million grant to advance its novel therapeutics, including drugs and biologics that reduce endothelial dysfunction and loss of endothelial barrier integrity, which are central to the pathophysiology of viral and bacterial infections resulting in acute and severe lung injury. Recently, Mannin submitted a funding application to the Small Business Technology Transfer Grant administered by the U.S. National Institutes of Health to investigate specific applications of Mannin's therapeutic platform.